BRAF and neoplasm: Third, several molecular reviews for microsatellite instability (MSI) testing [37], RAS and BRAF mutations, pathological reports for tumor budding, [9] and desmoplastic reaction, and liquid biopsy with circulating tumor DNA detection [38] were not routine requirements in our primary cohort between January 2004 and January 2009.